인벤티지랩
389470KOSDAQ44.9 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
InventiZ Lab is a DDS (Drug Delivery System) platform company leveraging microfluidics-based Laminar-FLUIDigm™ technology to develop long-acting injectables and gene delivery solutions. It utilizes the IVL-DrugFluidic® platform for improved new drug development and the IVL-GeneFluidic® platform for LNP formulation services for mRNA vaccines, alongside expanding CDMO (Contract Development and Manufacturing Organization) operations. The company currently produces and sells Durahart SR-3 injectable solution and is advancing multiple drug candidates, including IVL3001, IVL3003, and IVL3004, through various clinical trials.
Number of Employees
73people
Average Salary
44.9M KRW
Score Calculation Basis
Detailed Financial Score
3.6x industry avg (risky)
Well below industry avg
Half of industry avg (excellent)
Avg ▲117.9% (2-year basis)
Avg ▼34.2% (2-year basis)
Avg ROE -91.6% (improving, 3yr)
Detailed News Sentiment
- Positive김주희 인벤티지랩 대표 “SC제형 플랫폼, 국내 다수 기업과 MTA.....
인벤티지랩의 새로운 SC 제형 플랫폼 기술 검증 시작으로 미래 성장 가능성이 높아짐.
- Positive'AI·진단' 꽂힌 대웅제약, 상반기 지분 투자사 살펴보니
대웅제약의 대규모 신규 투자로 인벤티지랩 관련 의료 AI 및 데이터 분야에 긍정적 영향 예상.
- Neutral탈모약도 세대교체?…제약사들 신약 개발에 속도
제약사들의 새로운 탈모 치료제 개발 동향이 언급되었으나, 특정 종목인 인벤티지랩에 직접적인 영향은 제한적임을 나타냄.
Detailed Momentum
Near 52w low (1%, downtrend)
1m -16.43% (strong drop)
Volume decreasing
Detailed Disclosure
- Neutral반기보고서 (2026.06)2026-08-26
